Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
Moldova
PMSI Republican Clinical Hospital "T.Mosneaga" ( Site 0002), Chisinau Romania
ARENSIA Exploratory Medicine ( Site 0001), Bucharest, Bucharest